OncoLize is preparing first human trials in pancreatic cancers and other aggressive tumor indications.
We localize the delivery of well-proven drugs inside or next to the tumor. This will increase tumor eradication, reduce side-effects, and keep effective treatment Triple A: Affordable and Accessible for All.
We are now raising our Series A funding of € 8.5 million in two steps…. Join us!
We have shown the concept to work, have several patents in national stages, and we can scale-up the products at minimal costs. With our extensive experience in setting-up controlled delivery start-up’s we aim to exit at year 6.
That being said, we at OncoLize believe and practice that our products should have impact for global issues. We will make these products available for campaignes in Low Income Countries through focused NGO-collaborations.
OncoLize is preparing first clinical trials to treat pancreatic tumors. Based on solid Proof-of-Concept data and its proprietary OCL platform the company will raise €8.5 Million in two steps. This will start trials in the Read more…
Mike de Leeuw was invited to write an expert column in a special feature of ‘Het Financieel Dagblad’ covering a.o. oncology development in the Netherlands. You can read the column here.
OncoLize will join the Dutch trade mission to China, hosted by our Prime Minister Mark Rutte and several cabinet members. OncoLize features prominent in the Life Sciences and Health group, visiting Beijing (9-10), Guangzhou (11), Read more…